Navigation Links
ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
Date:4/16/2008

FREDERICK, Md., April 16 /PRNewswire/ -- ImQuest Life Sciences today presented important new results on the development of their lead anti-HIV therapeutic development candidate, IQP-0410, and lead topical microbicide development candidate, IQP-0528. ImQuest scientists Robert W. Buckheit, Jr., Ph.D. (Executive Vice President and Chief Scientific Officer) and Karen M. Watson, M.S. (Manager, Topical Microbicide Research & Development) were invited to speak at The International Conference on Antiviral Research (ICAR), being held this week in Montreal, Quebec, Canada. ImQuest studies have demonstrated that each of these highly novel pyrimidinedione inhibitors act by two distinct mechanisms of action, preventing the entry of HIV into human cells and inhibiting the activity of a key HIV enzyme, reverse transcriptase.

Dr. Buckheit presented detailed mechanism of action evaluations performed with IQP-0410, demonstrating that the compound targets a newly defined conformational cell surface target formed upon attachment of the virus to prevent the entry of HIV into the cells. This molecular target will be exploited by ImQuest to develop even more potent HIV entry inhibitors. Ms. Watson reported on results of preclinical efficacy and safety testing on the related pyrimidinedione microbicide, IQP-0528, to prevent the sexual transmission of HIV worldwide. The ImQuest team also demonstrated that IQP- 0410 was highly effective against multi-drug resistant HIV, especially viruses derived from patients treated extensively with protease inhibitors. The studies included ImQuest co-authors Lu Yang, M.D., Tracy Hartman, M.S., Christa E. Buckheit and Robert W. Buckheit, III.

"Our results clearly indicate that the pyrimidinediones represent a completely new class of HIV inhibitor that may be of great benefit to the prevention of HIV infection as a topical microbicide, the therapeutic treatment of primary HIV infection, as well as a salvage therapy for patients failing
'/>"/>

SOURCE ImQuest Life Sciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
2. NovoCure presents results from breast cancer pilot study
3. Center for Connected Health Presents Growing Evidence of the Benefits of Technology to Improve Patient Satisfaction and Empowerment
4. Gourmetceuticals Presents Findings on Science You Can Eat at Experimental Biology 2008
5. 5W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation
6. CVS Caremark Presents at NCOA-ASA Conference on Companys Commitment to Recruiting and Retaining Mature Workers
7. RNR Public Relations Presents Perfect April Fools Day Feature Opportunity
8. New Jersey Hospital Association Presents Awards for Commitment to Healthcare
9. Brain stress system presents possible treatment
10. Joanne Steen Presents Grief Solutions at the Headquarters Marine Corps 2008 Casualty Conference
11. QueensLander Tours Presents an Adventure Boot Camp Cruise with John Spencer Ellis from Bravos The Real Housewives of Orange County
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 issue of The FASEB Journal ... a simple blood test. This test, called the "lymphocyte genome ... than ever before, but it may eliminate the need for ... likely to develop cancer in the future. , "The ... peoples, lives," said Diana Anderson, a researcher involved in the ...
(Date:9/30/2014)... HealthDay Reporter MONDAY, Sept. 29, 2014 ... -- artificial valves, hip replacements, surgical mesh and the like ... after their approval by the U.S. Food and Drug Administration, ... prominent nonprofit groups and published online Sept. 29 in ... medical device testing on lax oversight by the FDA. ...
(Date:9/30/2014)... 30, 2014 Edward D. Buckingham, M.D., ... has been approved to be a director of a ... Reconstructive Surgery (AAFPRS) fellowship program. The announcement came last ... Florida. , The Educational and Research Foundation for the ... It represents the finest postgraduate program in the world ...
(Date:9/30/2014)... NC (PRWEB) September 30, 2014 ... and caring individuals, National Children’s Oral Health ... $150,000 in grants to non-profit clinical partners. ... Affiliate Network and deliver comprehensive educational, preventive ... , Recipients include:,     Just ...
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- Herceptin is ... cancer called HER2-positive and should remain the standard of ... findings from a long-term clinical trial. HER2-positive breast ... of breast cancer, according to the Mayo Clinic. ... countries received either Herceptin (trastuzumab) or Tykerb (lapatinib) in ...
Breaking Medicine News(10 mins):Health News:New blood test determines whether you have or are likely to get cancer 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 4Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 2Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 3Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 3
... Dr. Jacob Bolotin Awards Presented at 2008 Convention, ... of,the Blind presented $100,000 in cash awards to ... achieving the,full integration of the blind into society ... Bolotin Awards honored ten innovators in the blindness,field ...
... 7 The Peer Group, a leading provider,of ... an,Informed Medical Communications (IMC) company, today announced the ... innovation in moderated,peer influence events whereby two Key ... data, product attributes, and prescribing,experience in a debate-style ...
... of potent, or ,high affinity, antibodies to fight infection. The ... it hinges on a single molecule, a growth factor, without ... do not yet understand about our immune system. In simple ... T cells, which help them. Ways in which these cells ...
... BETHLEHEM, Pa., July 7 MIKE AND IKE(R) Lemonade,Blends(TM) ... candy fans who are members of the facebook(R) community ... To view the Multimedia News Release, go to:, http://www.prnewswire.com/mnr/justborn/33812/ ... Foundation will encourage,their fans who are active on facebook(R) ...
... Corporation (Pink,Sheets: BDRR), a medical imaging and diagnostic ... Network (OTCFN), a division of National,Financial Communications Corp., ... president of OTCFN, said, "In 2007, Bederra generated,revenues ... $471,182, or,approximately $0.01 per share, and has some ...
... Engage Contract Sales Organization And Seek New Marketing ... Partner to Promote Product in UK -, ... DDSS) today announced that it has reacquired the sales and,marketing rights ... Recordati Ireland Ltd. (Recordati). To promote its,product in the UK, the ...
Cached Medicine News:Health News:National Federation of the Blind Awards $100,000 2Health News:The Peer Group Launches Xpert Xchange(SM), an Innovation in Medical Peer Influence Programs 2Health News:Finding suggests novel ways to boost vaccination or natural defenses 2Health News:Photos: MIKE AND IKE(R) Lemonade Blends(TM) and Alex's Lemonade Stand Foundation Join facebook(R) 2Health News:Photos: MIKE AND IKE(R) Lemonade Blends(TM) and Alex's Lemonade Stand Foundation Join facebook(R) 3Health News:Bederra Corporation Retains OTC Financial Network for Investor Relations 2Health News:Bederra Corporation Retains OTC Financial Network for Investor Relations 3Health News:Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product 2
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern ... Both established medical-device providers as well as new medical-device ... region, while simultaneously looking at ways to reduce the ... Using distributors is one of the effective means to ... devices distribution market in Eastern European and provides profiles ...
(Date:9/30/2014)... New York , September 30, 2014 ... - Global Industry Analysis, Market Size, Share, Growth and ... is expected to be worth USD 20.8 billion in ... billion in 2017, growing at a CAGR of 7.3% ... fundamental elements needed for various health purposes, especially to ...
(Date:9/30/2014)... 30, 2014 In a recent ... Fluid) backflow of the Eldor spinal needle 25G, 103 ... hole pencil point spinal needles of the same gauge ... Spinal anesthesia is an excellent type of regional anesthesia ... Anesthesia, etc. It is estimated that 100 ...
Breaking Medicine Technology:Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... Mich., Nov. 9 Thomson Reuters today ... leading clinical surveillance solution that enables hospitals to identify ... clinical quality and reduce total cost of treatment. , ... no additional cost. , CareFocus 2.0 contains ...
... Shire plc (LSE: SHP, Nasdaq: ... availability of INTUNIV (TM) (guanfacine) Extended Release ... of Attention-Deficit/Hyperactivity Disorder ( ADHD ) in children ... formulation of guanfacine, is the first and only nonscheduled alpha-2A ...
Cached Medicine Technology:Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 2Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 3Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 2Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 3Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 4Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 5Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 6Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 7
Remote Controlled, Easy to Use,Vision Tester Designed for Screening Children Ages 3 and Older.,Excellent for Pediatric and School Markets....
Contrast Sensitivity is Recognized as a Valuable Tool for Measuring Functional Vision Loss Caused by Early Eye Disease. Distance Test S.W.C.T. 201: Size 27in x 37 in (68.58cm x 93.98cm),Can be Wal...
Vision Testing for Infants and Non-Verbal Patients,Using Preferential Looking....
Adult: Letter Acuity, Astigmatic Clock, Binocular Balance, Supression, Fixation Disparity, Stereopsis...
Medicine Products: